Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Liver cancer肝癌

ICD-10: C22 — Malignant neoplasm of liver and intrahepatic bile ducts

Group: Cancer Specialty: Hepatobiliary Surgery

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
肝癌
English name
Malignant neoplasm of liver and intrahepatic bile ducts

Values written in Chinese are quoted as published by the source.

Also known as

  • HCC
  • Hepatocellular carcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 Not published Not published —
Radiotherapy 放疗 19000 – 53000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 12000 – 49000 CNY Average per case (full course) 全病程例均 2012–2014
Targeted therapy 靶向 28000 – 117000 CNY Per-item price 项目价 2025
Immunotherapy 免疫 32043 – 43803 CNY Per-item price 项目价 2024–2025
Liver transplant 肝移植 300000 – 600000 CNY Condition package price 病种打包全包价 2018–2019
Liver transplant (living or related donor) 肝移植（活体／亲属供肝） Not published Not published —

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 600000 CNY. Each row keeps its own data year and caliber.

7 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 14.4% 95% CI 14.2–14.5

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published by stage (the source publishes the overall figure only)

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院

    Shanghai 上海市

    National key clinical specialty

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

    Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.

  2. China-Japan Friendship Hospital中日友好医院

    Beijing 北京市

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Respiratory Medicine #2, Thoracic Surgery nominated in the Fudan list.

  3. Guangdong Provincial People's Hospital广东省人民医院

    Guangzhou 广州市

    National key clinical specialty

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

  4. Jiangsu Province Hospital江苏省人民医院（南京医科大学第一附属医院）

    Nanjing 南京市

    National key clinical specialty

    Also ranked: General Surgery nominated, Otorhinolaryngology nominated in the Fudan list.

  5. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院

    Wuhan 武汉市

    National key clinical specialty

    Also ranked: General Surgery #6, Urology #5, Gynecology #2 in the Fudan list.

  6. Hunan Provincial People's Hospital湖南省人民医院

    Changsha 长沙市

    National key clinical specialty

    Published research

    5 more published studies

    PubMed indexes 7 papers on this condition that name this hospital.

  7. First Hospital of China Medical University中国医科大学附属第一医院

    Shenyang 沈阳市

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Nuclear Medicine 核医学 #9, General Surgery nominated, Urology nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Liver cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Integrative Multimodal Imaging and Multi-omics Profiling of HCC Heterogeneity: a Translational Exploratory Study Leveraging CEUS, Elastography, SMI, PAI, Multi-omics Analysis, and AI-driven Modeling to Advance Precision Diagnosis and Therapeutic Optimization

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT07101237

  2. Study Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma

    Hospital
    Nanfang Hospital
    Status
    Recruiting
    Registry
    NCT06623474

  3. Study An Exploratory Clinical Study on the Safety and Efficacy of Autologous Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CG-102-12C) in the Treament of Advanced Hepatocellular Carcinoma

    Lead investigator
    TingBo Liang · Director physician
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07039201

  4. Study Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma: A Prospective, Exploratory, Single-Arm Study (CLEAR-2)

    Hospital
    Huashan Hospital
    Status
    Recruiting
    Registry
    NCT07331883

  5. Study Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Multicenter, Prospective, Phase II Study

    Lead investigator
    Zhou Qunfang · Clinical Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06550921
43 more registered studies

  1. Study Hepatic Arterial Infusion Chemotherapy Compared With Transcatheter Arterial Chemoembolizationin Intermediate-advanced Huge Hepatocellular Carcinoma: a Multicenter Retrospective Study

    Lead investigator
    Zhou Qunfang · Clinical Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06641713

  2. Study Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study

    Lead investigator
    Zhou Qunfang · Clinical Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06333561

  3. Study Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Hepatocellular Carcinoma (HCC) Amenable for Surgical Resection

    Hospital
    The Second Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06492408

  4. Study A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)

    Hospital
    Zhongda Hospital Southeast University
    Status
    Recruiting
    Registry
    NCT06844357

  5. Study Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT07356531

  6. Study An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

    Hospital
    Beijing Youan Hospital, Capital Medical University
    Status
    Recruiting
    Registry
    NCT07479485

  7. Study A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (SIRT) Therapy and Hepatic Arterial Infusion Chemotherapy (HAIC) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma

    Lead investigator
    Li Qiang · Chief Physician of Hepatobiliary Surgery
    Hospital
    The First Affiliated Hospital of Jinan University
    Status
    Recruiting
    Registry
    NCT07070076

  8. Study A Phase 2, Single-Arm Study of Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy

    Lead investigator
    Xu Yong, MD · Secretary of the Party Committee & Principal Investigator
    Hospital
    Shenzhen Third People's Hospital
    Status
    Recruiting
    Registry
    NCT06563947

  9. Study Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

    Lead investigator
    Jianbo Chen · director
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05970666

  10. Study An Early Clinical Study to Evaluate the Safety and Efficacy of SN301A Cell Injection in the Treatment of Subjects with Glypican-3 (GPC3)-Positive Advanced Hepatocellular Carcinoma

    Lead investigator
    Qi Li · Head of Oncology
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT06652243

  11. Study Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA

    Hospital
    Zhujiang Hospital of Southern Medical University
    Status
    Recruiting
    Registry
    NCT06157060

  12. Study A Randomized Controlled Trial Evaluating Different Doses of Oral Zinc Supplementation in Combination With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07793695

  13. Study Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

    Hospital
    Beijing Hospital
    Status
    Recruiting
    Registry
    NCT05738980

  14. Study A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study of Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection in Patients With High Risk of Relapse After Radical Surgery or Ablation of Hepatocellular Carcinoma (HCC).

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05862337

  15. Study China Metastatic Liver Cancer Clinical Registry Cohort Database

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07602504

  16. Study A Multicenter, Open-label, Single-Arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of a Single Dose of MDN-001 Injection in Patients With Unresectable Primary Hepatocellular Carcinoma (HCC).

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT07391839

  17. Study The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study

    Lead investigator
    Yuan-Cheng Wang · Head of Radiology
    Hospital
    Zhongda Hospital Southeast University
    Status
    Recruiting
    Registry
    NCT07351669

  18. Study China Liver Cancer Clinical Registry Cohort Database (HEAL)

    Hospital
    XinHua Hospital
    Status
    Recruiting
    Registry
    NCT06777485

  19. Study Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

    Lead investigator
    Beicheng Sun · Director, Hepatobiliary Surgery
    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT04595864

  20. Study Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06383520

  21. Study Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT07059936

  22. Study Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06536998

  23. Study Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen mRNA Therapy Combined With PD-1 Monoclonal Antibody and TACE for Advanced Hepatocellular Carcinoma

    Lead investigator
    TingBo Liang · The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06995105

  24. Study A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer

    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT04806464

  25. Study Neoadjuvant TACE Plus Iparomlimab and Tuvonralimab （QL1706）and Adjuvant QL1706 in Resectable BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria: the TITAN-HCC Phase II Trial

    Lead investigator
    Lunxiu Qin · Professor
    Hospital
    Huashan Hospital
    Status
    Recruiting
    Registry
    NCT07268131

  26. Study Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China

    Lead investigator
    Qing XIe · Director of Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT05870969

  27. Study Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib and Tislelizumab for Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus: A Prospective, Multicenter, Single-arm Study

    Lead investigator
    Kai Li · Professor
    Hospital
    First Hospital of China Medical University
    Status
    Recruiting
    Registry
    NCT07483359

  28. Study Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study

    Lead investigator
    Zhou Qunfang · Clinical Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT06644430

  29. Study Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma

    Lead investigator
    Ping Liang · Professor
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT02851784

  30. Study A Prospective Phase II Study of Fatty Acid Degradation (FAD) Subtype-Guided Comprehensive Therapy for Unresectable Hepatocellular Carcinoma

    Lead investigator
    YU DE CAI · Professor
    Hospital
    Nanjing Drum Tower Hospital
    Status
    Not yet recruiting
    Registry
    NCT07314372

  31. Study A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT06779461

  32. Study A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation

    Lead investigator
    lucaide · Chief Physician/Professor
    Hospital
    Ningbo Medical Center Lihuili Hospital
    Status
    Not yet recruiting
    Registry
    NCT07310836

  33. Study A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

    Lead investigator
    Caide Lu · Chief Physician
    Hospital
    Ningbo Medical Center Lihuili Hospital
    Status
    Not yet recruiting
    Registry
    NCT07368023

  34. Study A Non-randomized Controlled, Prospective, Real-world Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

    Lead investigator
    Liyun Fu · Chief Physician
    Hospital
    Ningbo Medical Center Lihuili Hospital
    Status
    Not yet recruiting
    Registry
    NCT07553767

  35. Study The Impact of Different Antiviral Strategies on Tumor Prognosis in Patients With HBV-related Liver Cancer After Radical Treatment: A Prospective, Open-label, Non-randomized Clinical Study

    Hospital
    Shenzhen Third People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07120750

  36. Study Compare the Accuracy of Circulating Tumor DNA Longitudinal Monitoring Minimal Residual Disease and Microvascular Invasion Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

    Hospital
    Zhujiang Hospital of Southern Medical University
    Status
    Not yet recruiting
    Registry
    NCT06449846

  37. Study The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC) as First-line Treatment for Unresectable Hepatocellular carcinomaA Multicenter, Retrospective Clinical Study

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Not yet recruiting
    Registry
    NCT07724951

  38. Study Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

    Lead investigator
    Gu Jinyang · Director of Hepatobiliary and Pancreatic Surgery Department
    Hospital
    The First Affiliated Hospital of Chongqing Medical University
    Status
    Not yet recruiting
    Registry
    NCT07324473

  39. Study Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

    Hospital
    Nanfang Hospital
    Status
    Not yet recruiting
    Registry
    NCT07544121

  40. Study Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy:A Single-Arm, Multicenter Clinical Study

    Hospital
    Nanfang Hospital
    Status
    Not yet recruiting
    Registry
    NCT07537777

  41. Study Identification of a Novel 29-Gene-Based Subtype of Hepatocellular Carcinoma and Its Correlation With Immunotherapy Efficacy

    Lead investigator
    Junjie Xu · Associate Chief Physician
    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07100236

  42. Study A Real-World Study on Reducing the Risk of Liver Cancer in Chronic Hepatitis B Patients With a Family History of HBV-Related Liver Cancer.

    Lead investigator
    Guiqiang Wang · Chief physician
    Hospital
    Second Affiliated Hospital of Harbin Medical University
    Status
    Not yet recruiting
    Registry
    NCT07007286

  43. Study Phase I/II Study of CAR-T Cell Therapy Targeting GPC3 in Patients with Treated Advanced GPC3-Positive Hepatocellular Carcinoma

    Lead investigator
    Han weidong · Director of the Department of Biotherapeutics
    Hospital
    Chinese PLA General Hospital
    Status
    Not yet recruiting
    Registry
    NCT06641453

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 7 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院 Shanghai 上海市 Hepatobiliary Surgery 胰腺肿瘤 Level B https://www.shca.org.cn/home/news/content/id/297/pid/25651
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Hepatobiliary Surgery 普外科（肝胆外科） Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Guangdong Provincial People's Hospital广东省人民医院 Guangzhou 广州市 Hepatobiliary Surgery 胰腺中心 Level B https://www.gdghospital.org.cn/NewsHospital/info_itemid_67669.html
Jiangsu Province Hospital江苏省人民医院（南京医科大学第一附属医院） Nanjing 南京市 Hepatobiliary Surgery 肝胆外科 Level B https://www.jsph.org.cn/info/3031/71721.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Hepatobiliary Surgery 普通外科：肝脏外科 · Hepatobiliary Surgery 普通外科：胆胰外科 Level B https://www.tjh.com.cn/contents/934/27291.html
Hunan Provincial People's Hospital湖南省人民医院 Changsha 长沙市 Hepatobiliary Surgery 肝胆外科（肝胆医院） Level B http://www.hnsrmyy.com/index.php?catid=115
First Hospital of China Medical University中国医科大学附属第一医院 Shenyang 沈阳市 Hepatobiliary Surgery 器官移植科/肝胆外科 Level B https://www.cmu1h.com/features/specialty

7 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 8 ICD codes
Version Code Name in that version
ICD-10-WHO C22 Malignant neoplasm of liver and intrahepatic bile ducts
ICD-10-WHO C22.0 Liver cell carcinoma
ICD-10-WHO C22.1 Intrahepatic bile duct carcinoma
ICD-10-WHO C22.2 Hepatoblastoma
ICD-10-WHO C22.3 Angiosarcoma of liver
ICD-10-WHO C22.4 Other sarcomas of liver
ICD-10-WHO C22.7 Other specified carcinomas of liver
ICD-10-WHO C22.9 Liver, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24